XM005

XM005 is an experimental gene therapy candidate being developed by Hefei Xingmou Biotechnology for the treatment of glaucoma. As of early 2024, the program is in the preclinical research and activity validation stage. Hefei Xingmou Biotechnology (also known as StarryGene) specializes in ophthalmic gene therapies, focusing on the development of viral vector-based treatments for retinal and optic nerve diseases. XM005 is designed to address the underlying pathology of glaucoma, potentially through neuroprotection of retinal ganglion cells or regulation of intraocular pressure, although its specific molecular target and mechanism of action have not been publicly disclosed.